REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stem Cell Therapy Stemchymal® for Spinocerebellar Ataxia (SCA3 and SCA6)

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

REPROCELL-Therapy

More Like This

PR Newswire associated0

REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs

ReLive Biotechnologies Announces NDA Approval of SpheChon 10-70 spheroids/cm² by the HSA in Singapore, Marking a Milestone in ReLive’s Global Endeavors

SmartCella obtains approval for GMP manufacturing and quality control testing of cell therapies

JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma

PR Newswire associated0

Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells

PR Newswire associated0

S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial

Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform

PR Newswire associated0

TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)